Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Gabriel C. Caponetti; Bhavana J. Dave; Anamarija M. Perry; Lynette M. Smith; Smrati Jain; Paul N. Meyer; Martin Bast; Philip J. Bierman; Robert G. Bociek; Julie M. Vose; James O. Armitage; Patricia Aoun; Kai Fu; Timothy C. Greiner; Wing C. Chan; Warren G. Sanger; Dennis D. Weisenburger

doi:10.3109/10428194.2015.1034699

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Gabriel C. Caponetti, Bhavana J. Dave, Anamarija M. Perry, Lynette M. Smith, Smrati Jain, Paul N. Meyer, Martin Bast, Philip J. Bierman, Robert G. Bociek, Julie M. Vose, James O. Armitage, Patricia Aoun, Kai Fu, Timothy C. Greiner, Wing C. Chan, Warren G. Sanger, Dennis D. Weisenburger

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

Original language	English (US)
Pages (from-to)	3082-3089
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	56
Issue number	11
DOIs	https://doi.org/10.3109/10428194.2015.1034699
State	Published - Nov 2 2015

Keywords

BCL2
BCL6
Diffuse large B-cell lymphoma
MYC

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2015.1034699

Cite this

Caponetti, G. C., Dave, B. J., Perry, A. M., Smith, L. M., Jain, S., Meyer, P. N., Bast, M., Bierman, P. J., Bociek, R. G., Vose, J. M., Armitage, J. O., Aoun, P., Fu, K., Greiner, T. C., Chan, W. C., Sanger, W. G., & Weisenburger, D. D. (2015). Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome. Leukemia and Lymphoma, 56(11), 3082-3089. https://doi.org/10.3109/10428194.2015.1034699

Caponetti, GC, Dave, BJ, Perry, AM, Smith, LM, Jain, S, Meyer, PN, Bast, M, Bierman, PJ, Bociek, RG , Vose, JM , Armitage, JO, Aoun, P, Fu, K, Greiner, TC, Chan, WC, Sanger, WG & Weisenburger, DD 2015, 'Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome', Leukemia and Lymphoma, vol. 56, no. 11, pp. 3082-3089. https://doi.org/10.3109/10428194.2015.1034699

@article{8fbb7d25b8454385aecc04a0cb67f950,

title = "Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome",

abstract = "In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.",

keywords = "BCL2, BCL6, Diffuse large B-cell lymphoma, MYC",

author = "Caponetti, {Gabriel C.} and Dave, {Bhavana J.} and Perry, {Anamarija M.} and Smith, {Lynette M.} and Smrati Jain and Meyer, {Paul N.} and Martin Bast and Bierman, {Philip J.} and Bociek, {Robert G.} and Vose, {Julie M.} and Armitage, {James O.} and Patricia Aoun and Kai Fu and Greiner, {Timothy C.} and Chan, {Wing C.} and Sanger, {Warren G.} and Weisenburger, {Dennis D.}",

note = "Publisher Copyright: {\textcopyright} 2015 Informa UK, Ltd.",

year = "2015",

month = nov,

day = "2",

doi = "10.3109/10428194.2015.1034699",

language = "English (US)",

volume = "56",

pages = "3082--3089",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

AU - Caponetti, Gabriel C.

AU - Dave, Bhavana J.

AU - Perry, Anamarija M.

AU - Smith, Lynette M.

AU - Jain, Smrati

AU - Meyer, Paul N.

AU - Bast, Martin

AU - Bierman, Philip J.

AU - Bociek, Robert G.

AU - Vose, Julie M.

AU - Armitage, James O.

AU - Aoun, Patricia

AU - Fu, Kai

AU - Greiner, Timothy C.

AU - Chan, Wing C.

AU - Sanger, Warren G.

AU - Weisenburger, Dennis D.

PY - 2015/11/2

Y1 - 2015/11/2

N2 - In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

AB - In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2-and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

KW - BCL2

KW - BCL6

KW - Diffuse large B-cell lymphoma

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84947744551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947744551&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1034699

DO - 10.3109/10428194.2015.1034699

M3 - Article

C2 - 25827211

AN - SCOPUS:84947744551

SN - 1042-8194

VL - 56

SP - 3082

EP - 3089

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this